Analysis of prognostic factors related to primary superficial bladder cancer tumor recurrence in prophylactic intravesical epirubicin therapy

International Journal of Urology

Volumn 6, Issue 4, 1999, Pages 178-183

  Kondo, Tsunenori ^a,b,c   Onitsuka, Shiro ^a,b   Ryoji, Osamu ^b   Kihara, Takeshi ^b   Goto, Yukiko ^a,b   Satoh, Toshihiko ^b   Nakazawa, Hayakazu ^b   Toma, Hiroshi ^b  

^a Saiseikai Kurihashi Hospital   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c Saiseikai Kawaguchi General Hospital   (Japan)

Author keywords

Epirubicin; Intravesical instillation; Prognostic factor; Recurrence; Superficial bladder cancer

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN; MITOMYCIN C;

ADULT; AGE; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; TUMOR RECURRENCE; TUMOR VOLUME;

ADMINISTRATION, INTRAVESICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; EPIRUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECURRENCE; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0033512942     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.1999.06441.x     Document Type: Article

References (32)

1. 1 Catalona WJ. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Stamey TA, Vaughan Jr ED (eds). Campbell's Urology, 6th edn. WB Saunders Co., Philadelphia, 1992; 1094-158.
2. 2 Heney NM, Ahmed S, Flanagan MJ et al. Superficial bladder cancer: Progression and recurrence. J. Urol. 1983; 130: 1083-6.
3. 3 Kakizoe T, Matsumoto K, Tobisu K, Takai K. Growth and progression patterns of papillary superficial bladder cancer. Jpn. J. Urol. 1987; 78: 1065-70.
4. 4 Prout Jr GR, Koontz Jr WW, Coombs LJ, Hawkins IR, Friedell GH for National Bladder Cancer Collaborative Group A. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J. Urol. 1983; 130: 677-80.
5. 5 Huland H, Otto U, Droese M, Klöppel G. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: Influence on recurrence, progression and survival. J. Urol. 1984; 132: 27-9.
6. 6 Ohe H, Watanabe H, Mishina T, Kojima M, Nakagawa S. Intravesical instillation of adriamycin for bladder tumors. Cancer Chemother. Pharmacol. 1992; 30 (Suppl.): S45-9.
7. 7 Cersosimo RJ, Hong WK. Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J. Clin. Oncol. 1986; 4: 425-39.
8. 8 Calais da Silva F, Ferrito F, Brandáo T, Santos A. 4′-Epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer. Eur. Urol. 1992; 21: 42-4.
9. 9 Eto H, Oka Y, Ueno K et al. Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: A multicenter randomized trial. Cancer Chemother. Pharmacol. 1994; 35 (Suppl.): S46-51.
10. 10 Shuin T, Kubota Y, Noguchi S et al. A phase II study of prophylactic intravesical chemotherapy with 4′-epirubicin in recurrent superficial bladder cancer. Comparison of 4′-epirubicin and adriamycin. Cancer Chemother. Pharmacol. 1994; 35 (Suppl.): S52-6.
11. 11 Melekos MD, Dauaher H, Fokaefs E, Barbalias G. Intravesical instillations of 4-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: Results of a controlled prospective study. J. Urol. 1992; 147: 371-5.
12. 12 Okamura K, Murase T, Obata K et al. A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. Cancer Chemother. Pharmacol. 1994; 35 (Suppl.): S31-5.
13. 13 Watanabe N, Miyagawa I, Higashibori Y et al. Phase II study of intravesical chemoprophylaxis of epirubicin after transurethral resection of bladder tumors. Cancer Chemother. Pharmacol 1994; 35 (Suppl.): S57-9.
14. 14 Ryoji O, Toma H, Nakazawa H et al. A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Cancer Chemother. Pharmacol. 1994; 35 (Suppl.): S60-4.
15. 15 Aso Y, Kotake T, Akaza H et al. General Rules for Clinical and Pathological Studies on Bladder Cancer, 2nd edn. Kanahara Shuppan, Tokyo, 1993.
16. 16 Satoh M, Kisaki N, Orikasa S. EPIR short-term intravesical therapy: Tissue distribution. J. Urol. Surg. 1994; 7: 597-601.
17. 17 Lutzeyer W, Rübben H, Dahm H. Prognostic parameters in superficial bladder cancer: An analysis of 315 cases. J. Urol. 1982; 127: 250-2.
18. 18 Dalesio O, Schulman CC, Sylvester R et al. Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary tract cancer Cooperative Group. J. Urol. 1983; 129: 730-3.
19. 19 Melekos MD, Chionis HS, Paranychianakis GS, Dauaher HH. Intravesical 4′-epi-doxorubicin (epirubicin) versus Bacillus Calmette-Guérin. Cancer 1993; 72: 1749-55.
20. 20 Molares A. Long-term results and complications of intracavitary BCG therapy. J. Urol. 1984; 132: 40-7.
21. 21 Oates RD, Stilmant MM, Freedlund MC, Siroky MB. Granulomatous prostatitis following Bacillus Calmette-Guerin immunotherapy of bladder cancer. J. Urol. 1988; 140: 751-4.
22. 22 Baert L, Leonard A. Chronic bacterial prostatitis: 10 years of experience with local antibiotics. J. Urol. 1988; 140: 755-7.
23. 23 Sato N, Sumiya H, Isaka S, Shimazaki J. Prognostic factors for progression of superficial bladder cancer. Jpn. J. Urol. 1992; 83: 1263-9.
24. 24 Zincke H, Benson Jr RC, Hilton JF, Taylor WF. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: A prospective, randomized, stratified study with crossover design. J. Urol. 1985; 134: 1110-14.
25. 25 Mulders PFA, Meyden APM, Doesburg WH, Oosterhof GON, Debruyne FMJ, Members of the Dutch South-eastern Urological Collaborative Group. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. Br. J. Urol. 1994; 73: 403-8.
26. 26 Igawa M, Urakami S, Shirakawa H et al. Intravesical instillation of epirubicin: Effect on tumour recurrence in patients with dysplastic epitheliums after transurethral resection of superficial bladder tumour. Br. J. Urol. 1996; 77: 358-62.
27. 27 Kobashi K. Statistical analysis of recurrent factors in superficial bladder cancer. Jpn. J. Urol. 1993; 84: 1188-96.
28. 28 Narayana AS, Loening SA, Slymen DJ, Gulp DA. Bladder cancer: Factors affecting survival. J. Urol. 1983; 130: 56-60.
29. 29 Takashi M, Murase T, Mitsuya H et al. Statistical analysis of factors affecting recurrence in superficial bladder cancer. Jpn. J. Urol. 1987; 78: 39-49.
30. 30 Melekos MD. Prophylaxis of superficial bladder cancer with a modified intravesical epirubicin treatment schedule. Oncology 1993; 50: 450-5.
31. 31 Cumming JA, Kirk D, Newling DW, Hargreave TB, Whelan P. A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumour. Eur. Urol. 1990; 17: 20-2.
32. 32 Kurth K, van der Vijgh WJF, ten Kate F, Bogdanowics JF, Carpentier PJ, van Reyswoud I. Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder. J. Urol. 1991; 146: 1508-13.